BHCM
GOSS icon

Brevan Howard Capital Management’s Gossamer Bio GOSS Stock Holding History

Brevan Howard Capital Management’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,591
Closed -$395K – 2269
2025
Q4 		$395K Buy
1,591
+1,415
+804% +$323K ﹤0.01% 1221
2025
Q3 		$37.1K Buy
+176
New +$31K ﹤0.01% 1899
2025
Q2 		– Sell
-296
Closed -$26K – 1904
2025
Q1 		$26K Buy
+296
New +$27.4K ﹤0.01% 1109
2024
Q2 		– Sell
-267
Closed -$25.2K – 1181
2024
Q1 		$25.2K Buy
+267
New +$23.5K ﹤0.01% 956

Other funds holding GOSS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Brevan Howard Capital Management's GOSS Position: Q1 2026 in Review

Brevan Howard Capital Management sold out of Gossamer Bio (GOSS) in Q1 2026, closing a stake of 1,591 shares — an estimated $395K sold.

Brevan Howard Capital Management first reported a position in GOSS in Q1 2024 and held it in 4 quarters. The position peaked at $395K in Q4 2025. 181 funds tracked by Wall St. Rank hold GOSS as of Q1 2026.

  • Brevan Howard Capital Management reported no remaining Gossamer Bio position as of Q1 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 1,591 Gossamer Bio shares in Q1 2026, an estimated $395K.
  • Brevan Howard Capital Management first reported a position in Gossamer Bio in Q1 2024 and held it in 4 quarters.
  • Brevan Howard Capital Management's Gossamer Bio position peaked at $395K in Q4 2025.
  • 181 funds tracked by Wall St. Rank held Gossamer Bio as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.